|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatic progenitor cells in human liver tumor development显示文摘In recent years, the results of several studies suggest that human liver tumors can be derived from hepatic progenitor cells rather than from mature cell types. The available data indeed strongly suggest that most combined hepatocellular-cholangiocarcinomas arise from hepatic progenitor cells that retained their potential to differentiate into the hepatocytic and biliary lineages. Hepatic progenitor cells could also be the basis for some hepatocellular carcinomas and hepatocellular adenomas, although it is very difficult to determine the origin of an individual hepatocellular carcinoma. There is currently not enough data to make statements regarding a hepatic progenitor cell origin of cholangiocarcinoma. The presence of hepatic progenitor cell markers and the presence and extent of the cholangiocellular component are factors that are related to the prognosis of hepatocellular carcinomas and combined hepatocellular- cholangiocarcinomas, respectively. | Louis Libbrecht | 2006 | World Journal of Gastroenterology2006，12，39： | 24 |
| 2 | HBx or HCV core gene expression in HepG2 human liver cells results in a survival benefit against oxidative stress with possible implications for HCC development显示文摘 | Tamara Severi Sara Vander Borght Louis Libbrecht Lucas VanAelst Frederik Nevens Tania Roskams David Cassiman Johan Fevery Chris Verslype Jos F. van Pelt | 2007 | Chemico-Biological Interactions2007，，2： | 1 |
| 3 | Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease显示文摘AIM To develop a MRI-based method for accurate determination of liver volume(LV) and to explore the effect of long-term everolimus(EVR) treatment on LV in PCK rats with hepatomegaly. METHODS Thirty-one female PCK rats(model for polycystic-liverdisease: PCLD) were randomized into 3 groups and treatment was started at 16 wk, at the moment of extensive hepatomegaly(comparable to what is done in the human disease). Animals received: controls(n = 14), lanreotide(LAN: 3 mg/kg per 2 wk)(n = 10) or everolimus(EVR: 1 mg/kg per day)(n = 7). LV was measured at week 16, 24, 28. At week 28, all rats were sacrificed and liver tissue was harvested. Fibrosis was evaluated using quantitative image analysis. In addition, gene(quantitative RT-PCR) and protein expression(by Western blot) of the PI3K/Ak T/m TOR signaling pathway was investigated. RESULTS LV determination by MRI correlated excellent with the ex vivo measurements(r = 0.99, P < 0.001). The relative changes in LV at the end of treatment were:(controls) +31.8%;(LAN) +5.1% and(EVR) +8.8%, indicating a significantly halt of LV progression compared with controls(respectively, P = 0.01 and P = 0.04). Furthermore, EVR significantly reduced the amount of liver fibrosis(P = 0.004) thus might also prevent the development of portal hypertension. There was no difference in phosphorylation of Akt(Threonine 308) between LAN-treated PCK rats control PCK rats, whereas S6 was significantly more phosphorylated in the LAN group. Phosphorylation of Akt was not different between controls and EVR treated rats, however, for S6 there was significantly less phosphorylation in the EVR treated rats. Thus, both drugs interact with the PI3K/Ak T/m TOR signaling cascade but acting at different molecular levels.CONCLUSION Everolimus halts cyst growth comparable to lanreotide and reduces the development of fibrosis. m TORinhibition should be further explored in PCLD patients especially those that need immunosuppression. | Frederik Temmerman Feng Chen Louis Libbrecht Ingrid Vander Elst Petra Windmolders Yuanbo Feng Yicheng Ni Humbert De Smedt Frederik Nevens Jos van Pelt | 2017 | World Journal of Gastroenterology2017，23，30： | 1 |
| 4 | Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers显示文摘 | David Cassiman Louis Libbrecht Valeer Desmet Carl Denef Tania Roskams | 2002 | Journal of Hepatology2002，，2： | 1 |
| 5 | Hepatic stellate cells do not derive from the neural crest显示文摘 | David Cassiman Amanda Barlow Sara Vander Borght Louis Libbrecht Vassilis Pachnis | 2005 | Journal of Hepatology2005，，： | 1 |
| 6 | Alpha B-crystallin expression in human and rat hepatic stellate cells显示文摘 | David Cassiman Tania Roskams Jos van Pelt Louis Libbrecht Paula Aertsen Tina Crabbé Hugo Vankelecom Carl Denef | 2001 | Journal of Hepatology2001，，2： | 1 |
| 7 | N -glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis显示文摘 | Bram Blomme Sven Francque Eric Trépo Louis Libbrecht Dieter Vanderschaeghe An Verrijken Piet Pattyn Yves Van Nieuwenhove Dirk Van De Putte Anja Geerts Isabelle Colle Joris Delanghe Christophe Moreno Luc Van Gaal Nico Callewaert Hans Van Vlierberghe | 2011 | Digestive and Liver Disease2011，，4： | 1 |
| 8 | Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I显示文摘 | Julien Calderaro Philippe Labrune Guillaume Morcrette Sandra Rebouissou Dominique Franco Sophie Prévot Alberto Quaglia Pierre Bedossa Louis Libbrecht Luigi Terracciano G. Peter A. Smit Paulette Bioulac-Sage Jessica Zucman-Rossi | 2012 | Journal of Hepatology2012，，： | 1 |
| 9 | Hepatic Progenitor Cells in Hepatocellular Adenomas显示文摘 | Libbrecht Louis MD De vos Rita Ph D Cassiman David M D | 2001 | American Journal of Surgical Pathology2001，25，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员